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Gold nanoparticles for cancer 
radiotherapy: a review
Kaspar Haume1*, Soraia Rosa2, Sophie Grellet3, Małgorzata A. Śmiałek4, Karl T. Butterworth2, 
Andrey V. Solov’yov5, Kevin M. Prise2, Jon Golding3 and Nigel J. Mason1
Background
Cancer is one of the leading causes of death worldwide and the number of cancer-diag-
nosed patients is rapidly increasing, in part due to an ageing population, and is expected 
to reach 22 million cases in the next two decades (Stewart 2015). Currently, the main 
therapeutic approaches used to treat cancer are surgery, chemotherapy, and radiother-
apy, delivered separately or in various combinations (Sánchez-Santos 2012).
Surgery and radiotherapy are key players for treating primary non-metastasised solid 
tumours, but for patients with co-morbidities that are unfit for surgery, deep-seated 
tumours, especially those associated with major blood vessels, or brain tumours, com-
bined chemotherapy approaches are common.
Abstract 
Radiotherapy is currently used in around 50% of cancer treatments and relies on the 
deposition of energy directly into tumour tissue. Although it is generally effective, 
some of the deposited energy can adversely affect healthy tissue outside the tumour 
volume, especially in the case of photon radiation (gamma and X-rays). Improved 
radiotherapy outcomes can be achieved by employing ion beams due to the charac-
teristic energy deposition curve which culminates in a localised, high radiation dose 
(in form of a Bragg peak). In addition to ion radiotherapy, novel sensitisers, such as 
nanoparticles, have shown to locally increase the damaging effect of both photon and 
ion radiation, when both are applied to the tumour area. Amongst the available nano-
particle systems, gold nanoparticles have become particularly popular due to several 
advantages: biocompatibility, well-established methods for synthesis in a wide range 
of sizes, and the possibility of coating of their surface with a large number of different 
molecules to provide partial control of, for example, surface charge or interaction with 
serum proteins. This gives a full range of options for design parameter combinations, in 
which the optimal choice is not always clear, partially due to a lack of understanding of 
many processes that take place upon irradiation of such complicated systems. In this 
review, we summarise the mechanisms of action of radiation therapy with photons and 
ions in the presence and absence of nanoparticles, as well as the influence of some of 
the core and coating design parameters of nanoparticles on their radiosensitisation 
capabilities.
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In chemotherapy, pharmaceutical compounds that exert a cytotoxic effect disrupting 
mechanisms underpinning the rapid overgrowth of malignant cells are administered 
(Hanahan 2011; Joiner and van der Kogel 2009; Crawford 2013). Conventional chemo-
therapy is effective but also well-known for its severe side effects owing to the partially 
non-selective uptake of the chemotherapeutics both into healthy and cancerous cells 
in tissues and organs. Significant improvement has been made in recent years with the 
advent of nanomedicine, which provided an important addition to chemotherapy as a 
new medicine (Sun et al. 2014; Danhier et al. 2010).
Radiotherapy is a key treatment and is beneficial in the treatment of about 50% of all 
cancer patients (Delaney and Barton 2015). Such treatment relies on the deposition of 
energy (the dose) in tumour cells, typically by irradiation with either high-energy gamma 
rays or X-rays (photons), or energetic beams of ions, sufficient to damage the cancer cells 
or their vasculature and thus induce tumour death or nutrient starvation. However, like 
chemotherapy, photon radiotherapy is non-specific, since a significant dose can be deliv-
ered to healthy tissue along the track of the photons, in front and behind the tumour 
(Greish 2007; Hainfeld et al. 2008).
For radiotherapy, the central pathways to increase the therapeutic index, i.e. the ratio 
of treatment efficacy to side effects, are reversal of radiation resistance in tumour tis-
sue, enhancement of radioresistance in healthy tissue, increasing radiosensitisation 
in tumour tissue, and better confinement of the deposited dose to the tumour volume 
(Kwatra et al. 2013). In this review, we will focus on the latter two pathways through the 
use of nanoparticles to achieve radiosensitisation and ion beam radiation to achieve a 
higher, more localised dose. The underpinning research involved in this area is highly 
multidisciplinary, including such diverse fields as atomic cluster physics, collision stud-
ies, materials research, nanoparticle synthesis, analytical chemistry focused on char-
acterisation of the bio-nano interactions between the nanoparticles and the biological 
environment as well as mechanistic in  vitro and in  vivo studies. This is all aided by 
advanced imaging and by computational efforts to model the interactions between ions, 
biological matter, and nanoparticles.
In this review, we would like to sum up some key findings of the newly developed 
radiotherapy involving gold nanoparticles and bring up some of the mechanisms discov-
ered and methodologies developed. This interdisciplinary research attracts a lot of atten-
tion from various communities, thus providing both experimental and computational 
insights into investigations from molecular to cellular level.
The review is organised as follows: First we present the principal mechanisms of radio-
therapy using both photons and ions. Then the mechanisms of using nanoparticles (NPs) 
to achieve radiosensitisation is presented followed by the influence of several physico-
chemical properties of such NPs (size, material, coating, charge) and their impact on 
toxicity and biodistribution. Finally, the paper will conclude with a brief summary of the 
field and future challenges.
Conventional radiotherapy
Principles of radiotherapy
Radiotherapy treatments rely on the deposition of energy along the path of the incident 
radiation. A series of events occur on different time scales after irradiation of biological 
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medium and these can, in general, be referred to as the physical, chemical, and biological 
stages.
During the physical stage, the photons (or ions) interact with the medium, depositing 
energy, and either directly damage the cell by ionising fragmentation of the DNA or gen-
erate secondary species, such as low energy electrons or radicals, that can further dam-
age DNA. This happens within the sub-femtosecond time scale.
Although damage to other parts of a cell than DNA can also lead to its death [for 
example, damage to mitochondria (Kobayashi et  al. 2010; Pan et  al. 2009)], the most 
widely used proxy for determining the efficacy of radiotherapy is to monitor the amount 
of DNA strand breaks produced. For in  vitro work, using plasmid DNA is especially 
prevalent (Wyer et al. 2009; Folkard et al. 1993; Śmiałek et al. 2013, 2014).
Several studies have shown that the main pathway of DNA damage, from both X-rays 
and gamma rays, is through the production of water radicals with ca. 70% of damage 
caused by radicals and other reactive species—the most important being ·OH, NO· , H·, 
and H2O2—and 30% due to secondary electrons and direct fragmentation of the DNA 
(Kavanagh et al. 2013; Nikjoo et al. 2001; Emfietzoglou et al. 2005; Kwatra et al. 2013). 
These highly reactive radicals, particularly ·OH, can rupture molecular bonds and oxi-
dise DNA or proteins of intracellular structures, such as mitochondria or membranes, 
which affects the stability of the cell membranes and organelles. In addition to the 
damage produced by radicals, it has been shown that secondary electrons, produced 
in ionisation events, can cause DNA strand breaks as well through a process known as 
dissociative electron attachment (Pan et al. 2003). Secondary electrons can also further 
increase the radical yield by interacting with the water medium as shown in Fig. 1. The 
damage due to secondary species is referred to as the indirect damage and takes place 
at the chemical stage (times within microseconds after irradiation). And finally, during 
the biological stage (from microseconds and up), the damaged cells exhibit the conse-
quences of the radiation exposure. If exposed to a sufficiently high radiation dose, with 
appropriate dose rate and dose fractionation, the cell will die.
The damage caused to DNA by radiation can result in a range of various lesions, 
including base damage, single strand breaks (SSBs) or, less frequently, double strand 
Fig. 1 Illustration of mechanisms of radiation damage. Both photon and ion radiation (red wiggly and straight 
lines, respectively) may directly damage DNA (marked with yellow stars) or other parts of the cell, such as 
mitochondria (damage not shown), as well as ionise the medium thereby producing radicals and other reac-
tive species (represented here by the ·OH radical) as well as secondary electrons, which can cause indirect 
damage after diffusion (red stars). Secondary electrons may also react with the medium to further increase 
the number of radicals. See text for further details
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breaks (DSBs). In most cases, base damage and SSBs can be effectively repaired by the 
cell repair mechanisms, whereas DSBs, especially when induced at high levels (often 
referred to as “clustered” or “complex” damage), are difficult to get successfully repaired 
and are therefore more damaging to cells (Kobayashi et al. 2010).
The DNA may be successfully repaired ensuring continued, normal cell proliferation 
and function, or may result in misrepair, which in turn can lead to either its death or to 
mutations with a possibility of transforming a normal cell into a cancerous cell. Thus 
increasing the amount of clustered damage as well as sparing healthy tissue is the moti-
vation for seeking a better optimisation of radiation damage during treatment.
Herein, we focus on the external photon and ion beam radiotherapy and their interac-
tion with nanoparticles. The main difference between these two types of radiation lies in 
their ways of interaction with matter and modalities of the formation of the secondary 
species.
Photon‑based radiotherapy
In cancer radiotherapy, photons generally refer to either gamma or X-rays, with X-ray 
energies usually in the range between 80  keV and 25  MeV, predominantly in the 
8–18 MeV range for modern high-energy linear accelerators that are used to produce 
and form the radiation beam (Dendy and Heaton 2011). The photons effectively ionise 
biological matter and due to the relatively simple setup required to produce them, pro-
ton-based treatment protocols have been used with great success for decades.
A sufficient dose can kill any tumour cell but the concerns of the amount of damage 
to healthy tissue in the vicinity of the tumour limit how much radiation a patient can 
receive (Porcel et al. 2014; Hainfeld et al. 2008). Gamma and X-rays have an exponen-
tial dose deposition with tissue depth, therefore a significant fraction of the total dose is 
delivered to healthy tissue in front of and behind the target (Hainfeld et al. 2008; Krämer 
and Durante 2010). In an attempt to increase the dose delivered to the target while keep-
ing the dose delivered to surrounding, healthy tissue tolerable, lower-energy radiation 
from multiple angles can be used. The overlap of the beams on the cancer tissue ensures 
a high total dose on the target, but invariably leads to a much larger volume of low-dose-
irradiated healthy tissue (Kobayashi et al. 2010).
An important disadvantage of photon therapy is that cancer tissues can have, or 
develop, resistance to radiation; moreover, due to the physical extent of this tissue, it can 
be difficult to effectively irradiate the whole tumour, which may lead to its regeneration 
(Kwatra et al. 2013).
Ion‑based radiotherapy
To overcome the abovementioned disadvantages associated with the photon-based radi-
otherapy, the therapy based on ions as an alternative method achieved the lowering of 
the unwanted effects on healthy tissues and better control of the size and shape of the 
irradiated volume.
Ion radiotherapy refers to the use of ion beams as the radiation source, consisting of 
ions of hydrogen (protons), helium, carbon, or oxygen. Usually, hydrogen and helium 
ions are referred to as “light ions” and the others as “heavy ions”.
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The attractiveness of ion radiation stems from the characteristic interaction properties 
with matter, namely that the energy deposition is maximum for low ion velocities. This 
means that the energy deposition of an ion increases as it traverses tissue, producing 
radicals and secondary electrons along the track. This causes a strong enhancement of 
the linear energy transfer (LET, energy deposited per unit distance traversed in units of 
keV/µm) near the end of the track in what is called the Bragg peak (Tsujii et al. 2014). 
By tuning the incident energy of the ion, the location of the Bragg peak, which extends 
over only a couple of millimetres, can be directed into the tumour tissue leading to a 
very high, well-defined, and localised dose. For this reason ion-based therapy is consid-
ered superior when tumours are situated close to sensitive tissues or vital organs such as 
the spinal cord, brain, and eye (Kraft 1990). During therapy, a range of ion energies are 
delivered, leading to the production of a Spread-Out-Bragg-Peak (SOBP) (Krämer et al. 
2000). This increases the volume that can be treated but it also leads to a higher amount 
of radiation received in the entrance channel (the healthy tissue preceding the target).
The amount of deposited energy depends on the mass and energy of the incident ion, 
with heavier ions having, in general, a higher LET (Scifoni et al. 2010). However, irradia-
tion with heavier ions tends to deposit some energy beyond the target due to fragmenta-
tion of the incident ion near the Bragg Peak. This may produce lighter nuclear fragments 
which continue depositing some energy, potentially causing further damage to healthy 
tissue (Haettner et al. 2006).
The prediction of cell killing is not straightforward. When the LET of incident ions 
increases, the radical production increases as well, which may lead to a reduced number 
of radicals available to interact with the cell due to recombination of these radicals with 
each other (Usami et al. 2010; Terato et al. 2008).
Modelling radiation response
To make predictions of radiation effects, a popular simulation model of the effect of 
radiotherapy, local effect model (LEM) is used (Elsässer and Scholz 2007; Elsässer et al. 
2008). The premise of the LEM is that the local biological response to radiation is equal 
for equal doses and independent of the type of radiation. If the biological effect of a 
given dose is known for photon irradiation, then the biological effect of ion radiation 
can be calculated once the dose is known. The dose can be calculated from the LET of a 
given ion, which is known from experiments, and can be implemented to the model. The 
LEM model has shown good agreement with experiments (Krämer and Durante 2010; 
Elsässer et al. 2008; Combs et al. 2009).
Surdutovich and Solov’yov took another approach and formulated the so-called multi-
scale approach to the physics of radiation damage with ions (Surdutovich and Solov’yov 
2014). In this framework, all physical interactions (e.g. ionisation of matter as well as 
the production and transport of reactive species such as secondary electrons and free 
radicals) between ions and matter are accounted for quantitatively, which opens up a 
possibility to evaluate and predict biological consequences of radiation damage. The 
multiscale approach combines the information on the production of secondary species, 
their energy spectra, the transport of secondary species, and the interaction cross sec-
tions between electrons and radicals and biological matter. By thorough understanding 
of these nanoscale processes, one is able to evaluate the probability of single and double 
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DNA strand breaks as well as complex DNA lesions to be formed upon irradiation. 
From these data, survival curves can be obtained as a function of deposited radiation 
dose (Surdutovich and Solov’yov 2014). In this way, the multiscale approach bridges the 
femtosecond and sub-nanometre scale up to the biological timescale and dimensions. 
In a recent publication, the multiscale approach has been proved to successfully predict 
the survival probability of a number of mammalian cancerous and normal cell lines and 
some related phenomena, for example oxygen enhancement ratio (Verkhovtsev et  al. 
2016).
One of the important phenomena predicted and elaborated within the multiscale 
approach is the thermomechanical pathway of biodamage. It is caused by intense heating 
of the medium due to relaxation of the energy deposited by projectile ions to the mol-
ecules of the medium (Surdutovich and Solov’yov 2010; Surdutovich et al. 2013; de Vera 
et al. 2016). A rapid increase of temperature and pressure close to the ion’s path causes 
the formation of a shockwave which may damage DNA or other parts of the cell directly 
and increase the transport of reactive chemical species. Thermomechanical effects were 
recently shown to be important in the prediction of ion-induced radiation damage thus 
they need to be accounted for (Verkhovtsev et al. 2016).
Radiotherapy with gold nanoparticles
In addition to the use of NPs in nanomedicine, which has successfully improved the 
specificity of modern chemotherapeutics in recent years (Ranganathan et  al. 2012; 
Danhier et al. 2010; Sun et al. 2014), promising demonstrations of the radiosensitising 
potential of NPs in the last decade, both in vitro and in vivo, now mean that significant 
research efforts focus on NPs for improved dose localisation for radiotherapy (Hainfeld 
et al. 2008; Kwatra et al. 2013; Porcel et al. 2012; Liu et al. 2010; Polf 2011).
Gold NPs (AuNPs) in particular, have become popular since they have several advan-
tages, including good biocompatibility, straightforward synthesis in a wide range of 
sizes, and easy surface functionalisation by the attachment of ligands required to target 
cancer cells, and organelles therein, or improved life time in the bloodstream (McMa-
hon et al. 2011; Hainfeld et al. 2008; Kwatra et al. 2013; Malam et al. 2009; Barreto et al. 
2011; Carter et al. 2007; Liu et al. 2010). Additionally, as discussed later, AuNPs have a 
large interaction cross section with X-ray radiation up to about 1MeV as well as with ion 
radiation.
The contribution of AuNPs in increasing the radiotherapy efficiency is measured by 
the dose enhancement factor (DEF). The DEF of AuNPs is defined as the ratio of the 
radiation dose absorbed by the tumour cells in the presence of AuNPs to the dose 
absorbed in the absence of AuNPs (Muddineti et al. 2015). This may vary with the con-
centration and characteristics of the AuNPs and their location inside the cell (Butter-
worth et al. 2012; Hossain 2012).
Among other groups studying the benefit of AuNPs in combination with X-ray radio-
therapy, Zhang et  al. employed Monte Carlo simulations to show a possible radiosen-
sitisation with AuNPs and found that radiation beam will deposit a lower dose after 
having passed through the AuNP containing region, thus increasing the therapeutic 
ratio (Zhang et al. 2009).
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As previously mentioned, the main contribution to the killing of cells from radiother-
apy is through the production of free radicals. This is also the source of radiosensitisation 
when using NPs as they increase the radical production (Porcel et al. 2010; Verkhovtsev 
et al. 2015a).
The interaction between NPs and radiation is divergent for photons and ions, and will 
be briefly reviewed below.
Nanoparticles with photon radiation
X-rays and gamma rays interact with NPs mainly through the excitation and scattering 
of electrons of the NP (Hainfeld et  al. 2008; Kobayashi et  al. 2010). When the excited 
electron comes from an inner shell, the so-called Auger de-excitation processes are espe-
cially likely. This leads to one or more Auger electrons being emitted, the latter known as 
Auger cascades where more than 10 electrons can be emitted (Sancey et al. 2014; Porcel 
et al. 2010).
Auger electrons have energies below 5  keV and have been shown to be effective in 
damaging DNA directly in addition to ionising surrounding water molecules (Pan et al. 
2003; Butterworth et  al. 2013). All of the secondary electrons from the NPs may also 
interact with other NPs, resulting in further Auger electron emission (Kobayashi et al. 
2010; Porcel et  al. 2010) or they may be absorbed by the medium causing ionisation 
and radical formation (Hainfeld et al. 2008), see illustration in Fig. 2. Additionally, Por-
cel et al. suggested that the positively charged NPs (after emission of photo- or Auger 
electrons) could cause surrounding water molecules to become unstable and more eas-
ily dissociate, further increasing the radical yield in the environment of the NPs (Porcel 
et al. 2010).
a
b c
Fig. 2 Illustration of mechanisms of radiation damage in the presence of nanoparticles. In addition to the 
direct and indirect damage (yellow and red stars, respectively) to DNA or other parts of the cell (a), the inci-
dent radiation may also interact with NPs (b) (illustrated by dashed, wiggly arrows) and induce the emission of 
secondary electrons which can then react with the medium to increase the production of radicals and other 
reactive species (like ·OH radicals); secondary electrons produced by the radiation or by NPs may also induce 
further electron emission from NPs. c All the secondary species may diffuse and damage other parts of the 
cell (like mitochondria). See text for further details
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One of the proposed reasons for the observed radiosensitisation of NPs under photon 
irradiation is their higher interaction cross section with the radiation up until the mega-
voltage range compared to that of the water and soft tissue of the cells which contributes 
to the localisation of the dose. Due to the photoelectric effect scaling proportionally to 
(Z/E)3, where Z is the atomic number and E is the energy of the incoming photon, Auger 
emission is especially likely to take place for high-Z metals like gold, gadolinium, plati-
num, or silver (Kobayashi et al. 2010; Porcel et al. 2010; Coulter et al. 2013; Schlathölter 
et al. 2016), which have been shown to produce a larger number of Auger electrons when 
compared to the relatively light elements of biological tissue such as hydrogen, carbon, 
and oxygen. The increase in the interaction cross section of gold vs. soft tissue decreases 
at high energies, and it has indeed been found that the energy of the radiation plays a 
major role in the radiosensitisation effect. Rahman et al. found that low energy X-rays of 
80 kVp (peak kilovoltage), in combination with AuNPs were able to deliver a high DEF 
and that the effect increased with increasing concentration of AuNPs. DEF values of 4, 
20, and 24.6 were found for concentrations of 0.25, 0.5, and 1  mM, respectively. Fur-
thermore, at 150 kVp X-ray, the DEF increased from 1.4 to 2.2 for 0.5 and 1 mM AuNPs, 
respectively (Rahman et al. 2009).
In the clinical context, radiotherapy is often delivered using MeV X-rays, since keV 
photons have less penetration in tissue and would only be able to treat superficial 
tumours (Rahman et al. 2009). Despite the much lower interaction cross section at these 
energies, experiments show a radiosensitisation effect nonetheless (Butterworth et  al. 
2013). McMahon et al. (2011) showed computationally that the radiosensitisation seen 
with photons in these energies is caused by the interaction of NPs with secondary spe-
cies produced by ionisation of the water medium rather than with the radiation itself.
Particularly efficient for cell killing is the induction of “complex damage” due to the 
difficulty in successfully repairing such damage (as described above). For example, Por-
cel et al. showed an increase in the DSB/SSB ratio in plasmid DNA when using platinum 
NPs with ion radiation (Porcel et al. 2010), and increased amount of strand breaks was 
also observed by Xiao et al. (2011) who used AuNPs irradiated by electrons.
The local effect model (LEM) was used by Lin et  al. (2015) to simulate the effect of 
AuNPs under X-ray and proton radiation on cell killing. Their study showed that the 
uptake of NPs into cells is crucial for proton therapy but less so for photon therapy 
where AuNPs located in the intercellular medium can generate radicals that migrate and 
contribute to DNA damage. It should be mentioned that the simulation only included 
DNA damage, which may not be the only target in the cell and furthermore, it accounted 
only for direct interaction between the radiation and the NPs, thus excluding the inter-
action between NPs and secondary species, as described above.
However, it should be noted that although producing DNA strand breaks is an impor-
tant factor in inducing cell death and most experiments monitor the increase in SSBs 
and DSBs, it is by no means the only target in cancer cells for nanoparticle radiosensiti-
sation (Kobayashi et al. 2010; Štefancikova 2014; McQuaid et al. 2016).
Another potential target is the mitochondria, as disruption of their membrane poten-
tial can lead to apoptosis. AuNPs have been found to induce oxidation of the mitochon-
drial membrane protein cardiolipin and also the disruption of mitochondrial membrane 
potential. Depolarisation of the membrane potential may be due to increased radical 
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production promoted by NPs themselves, and oxidation of cardiolipin causes the release 
cytochrome c. Both processes can trigger apoptosis and thus contribute to enhanced 
radiosensitisation (Taggart et al. 2014, 2016).
Nanoparticles with ion radiation
In addition to the interaction between NPs and the secondary electrons produced by 
the ionisation of the medium by the ion radiation, it was recently shown in a theoretical 
study that metal NPs in combination with ion radiation significantly increase the sec-
ondary electron yield, compared to that of pure water, due to excitation of plasmons in 
the NP Verkhovtsev et al. (2015a, b).
Plasmons are the excitations of delocalised electrons of the material and can be effi-
ciently excited especially in metals. Verkhovtsev et al. showed that an order of magni-
tude increased the production of low energy electrons from metal NPs, compared to a 
similar volume of water, as the result of collective electronic excitation in the NP Verk-
hovtsev et al. (2015a, b). Specifically, it was shown that noble metal NPs are superior to, 
for example, gadolinium NPs because of the energy of the surface plasmon, which in 
noble metals is higher than the ionisation potential, such that the relaxation of plasmon 
excitations can cause the emission of an electron.
The effect of collective excitation was also shown for carbon-based NPs, although the 
effect is not as strong as for other metal systems like gold or platinum (Verkhovtsev et al. 
2015c). Due to the fact that the plasmon resonance energy for carbon NPs occurs at 
higher energies than for NPs of noble metals, it was proposed that NPs made of a com-
bination of materials with different plasmon resonance energies will be able to exploit 
a larger spectrum of ion energies, leading to a more efficient electron production from 
such NPs.
Physico‑chemical properties of NPs and their role in radiosensitisation
 There are several aspects to consider when developing new NPs such as the material 
they should be constructed from, their shape and size, the surface coating, and the net 
charge on the NP.1 All of these parameters influence cellular uptake and the biological 
response of cells as well as their interaction with radiation. Finding the optimal design is 
a non-trivial problem due to the large number of tuneable parameters. Here, we will 
overview some of the key parameters.
Size
The size of NPs used for radiosensitisation affects both how they interact with the bio-
logical system and how they interact with the radiation.
The biodistribution and route of elimination from the body are strongly depend-
ing on the size of the NPs. To avoid accumulation of NPs in organs such as heart and 
liver, causing potential long-term side effects, metal NPs should be eliminated from the 
body within a few days, which will still provide a window for radiotherapy with NPs pre-
sent. This is best achieved through renal clearance which is dependent on the size of 
1 Changed “Parameters of ” to “Physico-chemical properties of ” since this was requested by the reviewer for the para-
graph in the introduction, and so to keep it the same.
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the NPs (Alric et al. 2013; Barreto et al. 2011; Sancey et al. 2014). NPs with a hydrody-
namic diameter greater than 10 nm are more likely to be captured by the liver, whereas 
NPs smaller than 6 nm are usually eliminated by renal clearance independently of their 
charge (Longmire et  al. 2008; Bertrand and Leroux 2012; Moghimi et  al. 2012; Alexis 
et al. 2008; Almeida et al. 2011; Albanese et al. 2012; Owens and Peppas 2006; Choi et al. 
2007). NPs between 6 and 10 nm can also be eliminated via renal clearance, although 
in this case, positively charged NPs are eliminated faster than negative or neutral NPs 
(Longmire et al. 2008).
Although current data point to a maximum cell uptake by NPs between 20 and 60 nm 
(Albanese et  al. 2012; Chithrani et  al. 2006; Zhang et  al. 2009; Perrault et  al. 2009), 
smaller NPs still accumulate in tumours due to the enhanced permeability and reten-
tion effect (EPR) (Sancey et al. 2014). Smaller NPs will also tend to diffuse further into 
tumour tissue from the bloodstream, and therefore present a more even distribution in 
larger tumours than larger NPs. This may counteract the lower active uptake and the 
faster elimination from the blood stream of small NPs (Albanese et  al. 2012; Perrault 
et al. 2009).
Regarding toxicity of AuNPs, some studies have concluded that toxicity is minimal for 
NPs below 5 nm and above 50 nm, but severe at intermediate sizes (Akhter et al. 2012). 
Other studies have shown toxicity for AuNPs of diameter 3, 8, and 30 nm, but not for 5, 
6, 10, 17, or 48 nm (Vijayakumar and Ganesan 2013). This is clearly a complex question, 
and further research is necessary to define mechanisms of toxicity of AuNPs.
When considering the interaction between NPs and radiation, the size of the NPs is 
also important. As AuNPs become larger, more of the ionising events from interaction 
with secondary electrons and radiation occur in the bulk of the NPs, reducing the dose 
deposited in the medium around the NP (McMahon et  al. 2011). Carter et  al. (2007) 
found that the production of low energy electrons was increased for 3  nm NPs com-
pared with 6 nm NPs, and Lin et al. (2015) found improved cell killing in their theoreti-
cal study for 2 nm AuNPs compared to sizes up to 50 nm because secondary electrons 
formed in larger NPs have a higher probability of dissipating their energy inside the NP 
before reaching the surface.
Surface charge
A positive charge on the surface of NPs is thought to improve the uptake into cells due 
to its interaction with the negatively charged lipid membrane (Beddoes et al. 2015; Alba-
nese et al. 2012; Yah 2013; Hirsch et al. 2013; Kalay et al. 2014). Positively charged NPs 
could also selectively target cancer cells because of the glycocalyx structure, which, 
besides often being larger, can be more negatively charged on some cancer cells (Stylian-
opoulos et al. 2013; Sarin 2010). This glycocalyx is composed of different glycoproteins, 
and glycosaminoglycans, which can influence the membrane organisation, signal trans-
duction, and possibly enhance endocytosis (Paszek et al. 2014).
Although the amount of charge on NPs is linked to the cell membrane penetration, the 
exact optimal amount of charge is unknown (Beddoes et al. 2015). Da Rocha et al. (2013) 
showed computationally that the uptake pathway is dependent on the amount of charge 
and for neutral or slightly cationic NPs, a passive membrane translocation was favoured, 
whereas for highly cationic NPs, an endocytosis-mediated uptake was dominant. Due to 
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the more pronounced interaction, positively charged NPs induce higher local distortion 
of the membrane and can perturb the transmembrane potential thereby interfering with 
certain cell functions, such as ion transport, and increase the probability of pore forma-
tion in the membrane (Beddoes et al. 2015; Albanese et al. 2012).
When a foreign object is introduced to the bloodstream, specialised serum proteins 
called opsonins will adsorb onto the surface of the object, labelling it for clearance from 
the body (Malam et  al. 2009). Since these proteins have a negative charge, positively 
charged NPs will tend to be eliminated faster in vivo compared to neutral or negatively 
charged NPs (Alric et al. 2013; Alexis et al. 2008). This can be circumvented by appropri-
ately coating the NP, as will be discussed below.
Concentration of NPs
It was recognised by Hainfield et al. (2004) in some of the earliest studies of NPs as a 
radiotherapy agent, that the concentration of NPs in tumour tissue plays an important 
role in the radiosensitisation effects, and it has since been reported that the concentra-
tion of AuNPs plays a larger role in radiation dose enhancement than their size (Mes-
bahi et al. 2013; Babaei and Ganjalikhani 2014). Brun et al. investigated the relationship 
between plasmid DNA:AuNP ratio, incident X-ray energy, and AuNP size (Brun et al. 
2009). Across a range of DNA:AuNP ratios between 1:1 and 1:10, photon energies 
from 14.8 to 70 keV, and sizes in the range of 8–92 nm, they found that the best radio-
enhancement (sixfold improvement relative to the controls) was achieved with 37.5 nm 
AuNPs, at ratio of 1:1 DNA:AuNP, and an energy of 50 keV (Brun et al. 2009).
Coating of nanoparticles
Coating of NPs can to help control the interaction of NPs with the proteins of the blood-
stream (Monopoli et al. 2011, 2012; Krpetić et al. 2014). Additionally, NP coating can be 
used to target specifically the tumour cells in the body (see “Active targeting” section and 
references therein). The targeting strategies that are being employed in order to ensure a 
sufficient concentration of NPs in tumour cells can be divided into two categories: passive 
targeting and active targeting (Akhter et al. 2012). In passive targeting, one takes advan-
tage of the higher endocytic uptake of cancer cells and leaky vasculature around tumours 
which allow for higher uptake of NPs than in healthy tissues (Barreto et al. 2011), while 
in active targeting, the NPs are functionalised with specific molecules that interact with 
receptors known to be selectively present in tumour cells (Salvati et al. 2013).
The applied coating also allows for controlling of the charge of the surface of the NPs. 
In addition to the interactions with opsonin proteins, that were already mentioned, 
the surface charge plays a role in the stability of AuNPs (for example, their tendency 
to aggregate) in aqueous solution and in the body (Alkilany and Murphy 2010). Coat-
ing of NPs can therefore provide partial control of life time and uptake dynamics of the 
AuNPs (Chithrani et al. 2009; Thierry and Griesser 2012; Saptarshi et al. 2013; Krpetić 
et al. 2011). One concern, however, when applying coating to NPs intended for radio-
sensitising agents is that the coating may absorb secondary electrons emitted from the 
metal core. Although radiosensitisation has been shown for coated AuNPs (Liu et  al. 
2010; Zhang et al. 2012), the coating may reduce the amount of radicals produced in the 
process, as recently shown by Gilles et al. (2014).
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Passive targeting
When the organism recognises a foreign body in the bloodstream, specialised serum 
proteins called opsonins will adsorb on the surface of the body labelling it for clear-
ance from the body (Malam et al. 2009). It has been shown that this can be prevented 
by attaching appropriate molecules on the surface of the NPs, for example poly(ethylene 
glycol) (PEG) (Alexis et al. 2008; Otsuka et al. 2003; Illés et al. 2014) (see Fig. 3 for an 
illustration of a PEG-coated AuNP). It is thought that PEG-coating of NPs provides a 
repelling force on the opsonins thus unlabelling them to cover their surface (Thierry and 
Griesser 2012; Otsuka et al. 2003). Since NPs tend to concentrate in tumour tissue as a 
consequence of abnormal blood vessel wall formation around tumour tissue and poorly 
developed lymphatic system that limits drainage of macromolecules from tumour tis-
sue (Ranganathan et al. 2012), the enhanced permeability and retention effect (EPR) is 
observed in this case. Increasing the blood circulation time by coating with e.g. PEG 
thus leads to higher passive uptake due to the EPR effect. The ability of the coating layer 
to provide the passive targeting conditions depends on several factors, like the size of the 
NP core or the length and surface density of capping molecules and have been already 
investigated both computationally and experimentally (Otsuka et al. 2003; Walkey et al. 
2012; Kingshott et al. 2002; Haume et al. 2016; Lee et al. 2009).
Active targeting
Active targeting involves attaching to the surface of NPs other molecules that have spe-
cific affinities to interact with cancer tissues. The main motivation is to avoid relying on 
passive uptake through the EPR effect (Coulter et al. 2013). This has been achieved, for 
example, with antibodies (Shmeeda et  al. 2009), peptides (Chanda et  al. 2010; Kumar 
et al. 2012), folates (Samadian et al. 2016; Zwicke et al. 2012), aptamers (Li et al. 2015; 
Wu et al. 2015), hormones (Dreaden et al. 2009, 2012), and glucose molecules (Calvaresi 
and Hergenrother 2013; Gromnicova et al. 2013; Hu et al. 2015).
Combination targeting
It is possible to combine the two abovementioned targeting strategies. To utilise PEG 
for increased circulation time, the ratio of PEG to targeting ligand has to be optimised. 
An excess of targeting ligand will lead to reduced circulation time (Shmeeda et al. 2009), 
whereas an excess of PEG will dilute the effect of the active targeting groups. Dai et al. 
Fig. 3 Illustration of PEG-coated AuNPs. Output from simulation of 1.4 nm AuNPs coated with a 32 and b 60 
PEG molecules. Details in Ref. Haume et al. (2016)
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found that for combination coatings, the length of PEG molecules should not exceed the 
length of the targeting ligands in order to prevent PEG molecules blocking the receptor–
ligand interaction (Dai et al. 2014).
Gold nanoparticle toxicity
Despite the various advantages of AuNPs, they are relatively expensive and even if 
AuNPs are reported to be inert and biocompatible, more information about their tox-
icological profile still needs to be provided (Kwatra et  al. 2013). As mentioned above, 
NPs below 5 nm are often used for radiosensitisation purposes due to the relatively rapid 
elimination from the body, good uptake, and favourable interaction with radiation, but 
at these sizes AuNPs can become chemically reactive (Alkilany and Murphy 2010; Ionita 
et al. 2007; Zhang et al. 2003; Pan et al. 2009; Xia et al. 2006).
Previous work has focused on the potential toxicity of AuNPs. Tables 1 and 2 form a 
non-exhaustive list of the different toxicology studies conducted with differently sized 
AuNPs, various cell types, and using ranges of AuNPs concentrations. This toxicity can 
be measured on in vitro models, using different measurements. The most common one 
is the measure of the half maximal inhibitory concentration (IC50), the concentration of 
chemicals which gives a decrease of 50% of the cell viability.
From the tables, it can be concluded that the toxic potential of AuNPs varies depend-
ing on their size and applied coating. Moreover, the toxic potential can also differ for 
various cell types. Pan et  al. (2007) showed that the toxicity of coated AuNPs is size-
dependent but does not depend on the type of coating as, for example, sodium triph-
enylphosphine monosulfonate (TPPMS) and sodium triphenylphosphine trisulfonate 
(TPPTS) coatings have the same toxicity for different cell lines.
However, Tsoli et al. (2005) found 50% toxicity after exposure to 0.24 μM of 1.4 nm 
AuNPs for 24 h. They found that AuNPs can improve the toxicity for cancer cell as com-
pared to standard chemotherapy. For example, the IC50 on a melanoma cell line exposed 
to 1.4 nm AuNPs was 180 times lower than the IC50 after exposure to cisplatin (Tsoli 
et al. 2005).
Furthermore, altered gene expression has also been observed due to the presence of 
NPs causing phenotypic changes (Ng et al. 2015) and cytokine induction (Fujiwara et al. 
2015). NPs may also have a role in propagating the bystander effect (Thubagere and 
Reinhard 2010). The bystander mechanism is observed when non-irradiated cells behave 
as if they were irradiated due to signals received from their irradiated neighbours. This 
effect is mainly propagated through reactive nitrogen and oxygen species, oxidised DNA 
from apoptotic cells, and cytokine production and release (Havaki et  al. 2015). Since 
NPs seem to interfere with these mechanisms it is possible that they could potentially 
propagate bystander signalling. Thus determining the way NPs interact and modulate 
cell response could give further insights towards targeting specifically cancer cells and 
improving therapeutic outcomes.
Future challenges and outlook
Even though photon radiotherapy is the most common treatment for a number of can-
cers with high effectiveness, it can still be optimised in order to reduce the side effects 
and increase the survival of healthy tissue.
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Table 1 In vitro toxicology studies of cancer models to AuNP exposure for AuNPs smaller 
than 4 nm
MMPC1 and MMPC2 mixed monolayer gold clusters functionalised with quarternary ammonium and with carboxylic acid, 
respectively, TPPMS sodium triphenylphosphine monosulfonate, TPPTS sodium triphenylphosphine trisulfonate, PEG 
polyethylene glycol, GHS glutathione
Size (nm) Coating Cancer cell line Exposure Time (h) Toxicity Ref.
2 MMPC1 COS-1 0.38–3 μM 1–24 IC50 = 1.0 μM Goodman et al. 
(2004)MMPC2 IC50 > 7.37 μM
MMPC1 Red blood cells 0.27–833 μM IC50 = 1.1 μM
MMPC2 IC50 = 72 μM
3.5 ± 0.7 Lysine, 
poly(lysine)
RAW 264.7 
mouse mac-
rophage
10–100 μM 24–72 >100 μM after 
24 h
Shukla et al. 
(2005)
1.4 PH2PC6H4SO3H MV3, <0.4 mM 24 IC50 = 0.24 μM Tsoli et al. (2005)
BLM IC50 = 0.30 μM
1.1 GSH HeLa 5.6 mM 48 IC50 = 3130 μM Pan et al. (2009)
1.4 TPPMS IC50 = 48 μM
TPPMS, GSH IC50 = 181 μM
1.4 TPPMS HeLa Up to 10 mM 36 IC50 = 30 μM Pan et al. (2007)
SK-mel-28 J774A1 
IC50 = 30 μM
L929 
IC50 = 56 μM
TPPTS HeLa IC50 = 46 μM
1.9 BAECs 0.125-1 mM ~30% cell 
death at 1 
mM AuNPs 
exposure
Rahman et al. 
(2009)
1.9 Du-145 Up to 2 mg/ml 24 LD50 = 20 μM Coulter et al. 
(2012)MDA-MB-231 LD50 = 24.6 μM
L132 LD50 = 320 μM
Table 2 In vitro toxicology studies of  cancer models to  AuNP exposure for  AuNPs larger 
than 4 nm
CTAB cetyltrimethylammonium bromide, PEG polyethylene glycol
Size (nm) Coating Cancer cell line Exposure Time (h) Toxicity Ref.
4, 12, 18 CTAB, citrate, 
cysteine, 
glucose, 
biotin
K562 leukae-
mia
Human 1–250 nM 72 >25 μM Connor et al. 
(2005)
4.8 PEG HeLa 1–250 μM 48 IC50 = 0.205 mM Zhang et al. 
(2012)12.1 IC50 = 0.477 mM
27.3 IC50 = 0.448 mM
46.4 IC50 = 0.613 mM
33 CTAB, citrate A549 0–120 nM 48 IC50 ≈ 100 nM Patra et al. 
(2007)BHK21 No toxicity 
observed for 
BHK21 up to 
these concen-
trations
35.6 ± 6.7 Cetuximab 
antibody
Panc-1 100 nM IC50 ≈ 100 nM Glazer et al. 
(2010)Cama-1 NA
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It has already been shown that introducing various radiosensitisers may help to 
achieve this goal, and among others, NPs present a high potential for various modes of 
action in the cancerous cells. Nonetheless, although increasing radiotherapy efficacy 
using nanoparticles could potentially improve this survival rate in the clinic context, in 
this still-developing field there are many unknowns in the mechanisms of action both at 
the molecular and cellular level, as well as when considering their potential impact on 
cellular communication.
Increased radical production has been attributed to the presence of NPs even in the 
absence of radiation which can cause damage to the cellular components due to ROS 
being generated (Pan et al. 2009) triggering first the apoptosis and as a consequence the 
necrosis of the cell (Xia et al. 2006). Although numerous studies on the size, shape, and 
capping agent of NPs have been performed, it is still not clear what are the optimal con-
ditions for the highest targeting rate of cancerous cells; thus much more work in this 
field is required.
From the very basic knowledge of photoelectric and related effects it can be easily 
concluded, that there are clearly benefits in combining AuNPs with radiotherapy. Here 
likewise much work is still necessary in order to optimise not only the multi-parameter 
properties mentioned above, but also to predict the most efficient way in secondaries 
production. It was already shown that the surface modifications, which increase the cel-
lular uptake and make the passive or active targeting possible, may cap the secondary 
electrons in the close vicinity of the NP, thus preventing an efficient radiosensitisation. 
This implies that some new compromises between what has been known to work and 
the aimed actions must be explored.
There is a great amount of both experimental and theoretical work devoted to all 
possible parameters of NPs. Such great variability of sizes, shapes, and coatings associ-
ated with the differential cellular responses dependent on cancer types makes it at the 
moment difficult to establish any correlations or standard conditions for treatments; 
therefore, some clarification and organisation of the achievements of various communi-
ties must be done.
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